Market Currents
The FDA rejects an experimental diabetes drug co-developed by Bristol-Myers Squibb (BMY -2.8%)...
-
Thursday, January 19, 2012, 10:52 AM ETThe FDA rejects an experimental diabetes drug co-developed by Bristol-Myers Squibb (BMY -2.8%) and AstraZeneca (AZN -2.2%), asking for more clinical data to assess its safety and efficacy. Analysts said the drug could have generated ~$400M in global sales by 2016, but an FDA advisory panel had previously recommended against it, citing safety concerns.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
